ORIGINAL ARTICLE: K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Posted on October 22, 2008 by Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., Price, T. J., Shepherd, L., Au, H.-J., Langer, C., Moore, M. J., Zalcberg, J. R.

This study examined the mutation status of the K-ras gene in colorectal tumors from patients who were enrolled in a trial of cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR). A survival benefit was found among patients with tumors bearing wild-type K-ras but not among patients with tumors bearing mutated K-ras. Wild-type K-ras is essential in transmitting signals initiated by EGFR.

This entry was posted in Medicina. Bookmark the permalink.

Comments are closed.